Responses

Download PDFPDF

Autoantibodies and thrombophilia in RA: TNFα and TNFα blockers
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    "In Response to: Autoantibodies and thrombophilia in RA: TNF alpha and TNF alpha blockers-June 2004

    Dear Editor,

    There has been growing interest in studies evaluating the effects of various disease modifying agents on endothelial dysfunction in patients with rheumatoid arthritis due to the predictive value of such properties on endothelial function on increased or decreased risk of cardiovascular events. We, therefore, read with great interest the article by Doctors Ferraciolo and Gremese in the June 2004 issue...

    Show More
    Conflict of Interest:
    None declared.